Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.
Humans
Muscarinic Antagonists
/ therapeutic use
Adrenergic beta-2 Receptor Agonists
/ therapeutic use
Administration, Inhalation
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Adrenal Cortex Hormones
/ therapeutic use
Prescriptions
Bronchodilator Agents
/ therapeutic use
Drug Combinations
COPD
Economic impact
Multiple-inhaler triple therapy
National Health Systems
Single-inhaler triple therapy
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
25 Oct 2022
25 Oct 2022
Historique:
received:
09
09
2021
accepted:
09
09
2022
entrez:
26
10
2022
pubmed:
27
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations. At the same time, severe COPD treatment, that often require a combination of medicaments, represents a substantial economic burden for the National Health Systems (NHS). This study aimed to evaluate the potential saving deriving from the implementation in the prescription of the two currently available single-inhaler triple therapies (SITTs) versus the currently used multiple-inhaler triple therapies (MITTs) in an eligible COPD population residing in the Apulia Region. A budget impact model was developed hypothesizing the progressive replacement of the different MITTs on the reference market (Scenario A) with the pre-established SITTs, assuming a degree of penetration of 30%, 50% and 100% (Scenario B). Drug costs were based on prices published on the Official Gazette and therapy durations were based on prescribing information over the year 2019 (IQVIA™ prescription dataset). Our analysis showed that the extemporaneous MITT with the highest prevalence on the reference market was the inhaled corticosteroids/long-acting β A pre-fixed ICS/LAMA/LABA SITT is cost-saving, compared to the different currently used extemporaneous MITTs. Clinicians should consider the potential benefits of finding less expensive regimens while maintaining adequate efficacy in the prescriptive decision making process of COPD patients.
Sections du résumé
BACKGROUND
BACKGROUND
The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations. At the same time, severe COPD treatment, that often require a combination of medicaments, represents a substantial economic burden for the National Health Systems (NHS). This study aimed to evaluate the potential saving deriving from the implementation in the prescription of the two currently available single-inhaler triple therapies (SITTs) versus the currently used multiple-inhaler triple therapies (MITTs) in an eligible COPD population residing in the Apulia Region.
METHODS
METHODS
A budget impact model was developed hypothesizing the progressive replacement of the different MITTs on the reference market (Scenario A) with the pre-established SITTs, assuming a degree of penetration of 30%, 50% and 100% (Scenario B). Drug costs were based on prices published on the Official Gazette and therapy durations were based on prescribing information over the year 2019 (IQVIA™ prescription dataset).
RESULTS
RESULTS
Our analysis showed that the extemporaneous MITT with the highest prevalence on the reference market was the inhaled corticosteroids/long-acting β
CONCLUSION
CONCLUSIONS
A pre-fixed ICS/LAMA/LABA SITT is cost-saving, compared to the different currently used extemporaneous MITTs. Clinicians should consider the potential benefits of finding less expensive regimens while maintaining adequate efficacy in the prescriptive decision making process of COPD patients.
Identifiants
pubmed: 36284319
doi: 10.1186/s12913-022-08640-9
pii: 10.1186/s12913-022-08640-9
pmc: PMC9595082
doi:
Substances chimiques
Muscarinic Antagonists
0
Adrenergic beta-2 Receptor Agonists
0
vilanterol
028LZY775B
Adrenal Cortex Hormones
0
Bronchodilator Agents
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283Informations de copyright
© 2022. The Author(s).
Références
Int J Chron Obstruct Pulmon Dis. 2020 Oct 07;15:2433-2440
pubmed: 33116458
Respir Med. 2008 Jan;102(1):92-101
pubmed: 17881206
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
Int J Chron Obstruct Pulmon Dis. 2020 Jul 10;15:1621-1632
pubmed: 32764908
PLoS One. 2014 Jun 27;9(6):e101228
pubmed: 24971791
Int J Chron Obstruct Pulmon Dis. 2017 Oct 06;12:2917-2928
pubmed: 29062229
Respir Med. 2007 Nov;101(11):2312-20
pubmed: 17681461
J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):474-85
pubmed: 26372466
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Lancet. 2018 Mar 17;391(10125):1076-1084
pubmed: 29429593
Monaldi Arch Chest Dis. 2002 Feb;57(1):3-9
pubmed: 12174698
J Med Econ. 2011;14(4):486-96
pubmed: 21679019
Int J Chron Obstruct Pulmon Dis. 2019 Nov 29;14:2681-2695
pubmed: 31819401
Respir Med. 2022 Jun;197:106807
pubmed: 35429764
Rev Assoc Med Bras (1992). 2021 Aug 13;67Suppl 1(Suppl 1):97-101
pubmed: 34406300
Eur Respir J. 2006 Jan;27(1):188-207
pubmed: 16387952
Eur Respir Rev. 2010 Jun;19(116):113-8
pubmed: 20956179
Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981
pubmed: 30587953
ERJ Open Res. 2021 Mar 22;7(1):
pubmed: 33778055
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2384-2385
pubmed: 32371047
Arch Bronconeumol. 2020 Apr;56(4):242-248
pubmed: 35373739
Lancet. 2016 Sep 3;388(10048):963-73
pubmed: 27598678
Pulm Pharmacol Ther. 2020 Feb;60:101879
pubmed: 31866498
Lancet. 2017 May 13;389(10082):1919-1929
pubmed: 28385353
Expert Opin Pharmacother. 2018 Aug;19(11):1279-1287
pubmed: 29985096
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712